- ￥1338 - 9188
- abinScience
- France
- MD492010
- 2026年04月26日
- Mouse
- Mouse
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 亚型：
IgG2a, kappa
- 形态：
Liquid
- 保存条件：
-20°C
- 克隆性：
单克隆
- 适应物种：
Mouse
- 保质期：
twelve months
- 级别：
一抗
- 供应商：
武汉益普生物科技有限公司
- 宿主：
Mouse
- 抗体英文名：
InVivoMAb Anti-Mouse CD19 & CD8 Bispecific Antibody (SAA2742)
- 规格：
50μg/100μg/1mg
| 规格： | 50μg | 产品价格： | ￥1338.0 |
|---|---|---|---|
| 规格： | 100μg | 产品价格： | ￥2288.0 |
| 规格： | 1mg | 产品价格： | ￥9188.0 |
| 产品名 | InVivoMAb Anti-Mouse CD19 & CD8 Bispecific Antibody (SAA2742) |
| 货号 | MD492010 |
| 宿主 | Mouse |
| 种属反应性 | Mouse |
| 克隆类型 | Monoclonal |
| 克隆号 | SAA2742 |
| Accession号 | P25918 & P01731 |
| 靶标 | B-lymphocyte antigen CD19, CD19, Cd19, Differentiation antigen CD19, CD8a, Cd8a, Lyt-2, Lyt2, T-cell surface glycoprotein CD8 alpha chain, T-cell surface glycoprotein Lyt-2 |
| 同种型 | IgG2a, kappa |
| 应用 | in vivo functional study |
| 内毒素水平 | Please contact with the lab for this information. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 纯度 | >95% as determined by SDS-PAGE. |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS pH 7.4 |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 说明 | For research use only. |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验How to Make Bispecific Antibodies
of two molecules of Fab’-A(mal) with two free SH-groups at the hinge of a single Fab’-B molecule (see Note 3 ). The remaining free SH groups on Fab’-B are alkylated, and the F(ab’)2 bispecific antibody product (Fab’-A x Fab’-B) is separated by gel filtration
[欢迎下载]：Antibody Engineering： Methods and Protocols
11 Selection of Internalizing Antibodies for Drug Delivery 12 Engineering Multivalent Antibody Fragments for In Vivo Targeting 13 Production of Recombinant Bispecific Antibodies 14 Expression and Isolation of Recombinant Antibody Fragments in E
【翻译】Development trends for monoclonal antibody cancer therapeutics
, after binding to a target, mAbs can recruit effector cells such as natural killer cells, macrophages or neutrophils, or activate complement to destroy the target3, 24, 25, 26, 27. These two modes of action are referred to as antibody-dependent cell cytotoxicity
技术资料暂无技术资料 索取技术资料
